According to a new market research study titled ‘Gastric Balloon Market to 2027 – Global Analysis and Forecasts by Product, Filling Material and End User. The global gastric balloon market is expected to reach US$ 152.1 Mn in 2027 from US$ 67.3 Mn in 2018. The market is estimated to grow with a CAGR of 9.7% from 2019-2027. The market is expected to grow due to growing hospital associated infections and government initiatives undertaken to promote the market growth, however, the high costs of the gastric balloon is hindering the market growth.
Get Sample PDF copy @ https://www.theinsightpartners.com/sample/TIPRE00003016/
Gastric balloons are being preferred for weight loss during recent days. Unlike other procedures for weight loss, the gastric balloons are non-invasive methods for managing weight loss. The gastric balloon is placed through the mouth and is pushed down the esophagus, while it is in its least dilated form. Once the balloon reaches the stomach, it is filled with the saline or gas with the help of a tube, which is removed out once the balloon has been placed. These balloons are inserted in the stomach for around 6 months in order to obtain proper weight loss.
Global gastric balloon market, based on end user was segmented as, bariatric surgeons, gastrointestinal endoscopists, nutritionists & aesthetic practitioners, and other end users. In 2018, bariatric surgeons segment held the largest share of the market, by end user. However, the gastrointestinal endoscopists segment is expected to grow at the fastest rate during the coming years attributing the rising preference of bariatric surgery for weight loss.
Ask For Discount @ https://www.theinsightpartners.com/discount/TIPRE00003016/
Company Profiles
- Allurion Technologies Inc.
- Apollo Endosurgery, Inc.
- ENDALIS
- Helioscopie Medical Implants
- LEXEL SRL
- MEDSIL
- Obalon Therapeutics, Inc.
- ReShape Lifesciences, Inc.
- Silimed
- Spatz FGIA, Inc.
Inorganic activities such as, agreement is a prominent parameter undertaken by industry players. For instance, in March, 2018, Reshape signed an agreement with Academy Medical LLC to sell its ReShape Balloon and ReShape vBloc products to U.S. Department of Defense (DoD) medical facilities. The developments performed by the companies are helping the market to grow in the coming years.
Obesity has been spreading at an epidemic rate during the recent years, specifically in the urban areas of the developed nations. As per estimates made by the WHO, during 2016, more than 1.9 billion adults, aged 18 years and older, were overweight. Of these over 650 million were obse. Also, an estimated 41 million children under the age of 5 years were overweight or obese. The prevalence of overweight and obesity among children and adolescents aged 5-19 has witnessed a dramatic from a minimal 4% in 1975 to above 18% in 2016. At present, obesity rates are significantly high in the United States, Mexico, New Zealand and Hungary, while they are lowest in Japan and Korea. Whereas, during the future years, obesity rates in countries such as Korea and Switzerland are anticipated to increase at the fastest rate.
Purchase this Report @ https://www.theinsightpartners.com/buy/TIPRE00003016/
The endoscopic intragastric balloon treatment is a non-surgical method to help lose weight in patients who suffer from obesity or morbid obesity. It is an endoscopic procedure, in which a balloon is inserted in the stomach, which occupies about half of the stomach’s space. The balloon remains in the stomach for a maximum of six months and it is meant to increase the feeling of satiety and limit food intake. Endoscopy offers ease in the placement as well as the removal of a gastric balloon, along with limited complications due to the non-surgical nature of the procedure. Also, the absence of incisions unlike other weight loss surgeries is expected to fuel the growth of the market in the future years.
Strategic Insights
Approvals and agreements were observed as the most adopted strategy in global gastric balloon industry. Few of the recent product launch and collaboration are listed below;
2018: In April, 2018, Apollo received approval from the Saudi Food and Drug Authority (SFDA) for the ORBERA365 Managed Weight Loss System. This approval enables the reach of ORBERA365 into the largest bariatric market in the Middle East with over 15,000 procedures performed per year.
2017: In November, 2017, Obalon and Sono Bello entered an agreement. Through the agreement the Obalon Balloon System would be used for non-surgical weight loss in Sono Bello centers across the US.
2015: In December 2015, Allurion received a CE mark allowing sale of the product in the European Union. The product has been made available in the weight loss centers in France, Italy and the United Kingdom.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com